- Home
- BRTX vs NXTC Comparison
BRTX vs NXTC Comparison
Compare BRTX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- NXTC
- Stock Information
- Founded
- BRTX 1997
- NXTC 2015
- Country
- BRTX United States
- NXTC United States
- Employees
- BRTX N/A
- NXTC N/A
- Industry
- BRTX Managed Health Care
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- NXTC Health Care
- Exchange
- BRTX Nasdaq
- NXTC Nasdaq
- Market Cap
- BRTX 12.6M
- NXTC 13.9M
- IPO Year
- BRTX N/A
- NXTC 2019
- Fundamental
- Price
- BRTX $1.67
- NXTC $0.46
- Analyst Decision
- BRTX Strong Buy
- NXTC Strong Buy
- Analyst Count
- BRTX 1
- NXTC 2
- Target Price
- BRTX $18.00
- NXTC $3.50
- AVG Volume (30 Days)
- BRTX 256.1K
- NXTC 338.3K
- Earning Date
- BRTX 08-12-2025
- NXTC 07-31-2025
- Dividend Yield
- BRTX N/A
- NXTC N/A
- EPS Growth
- BRTX N/A
- NXTC N/A
- EPS
- BRTX N/A
- NXTC N/A
- Revenue
- BRTX $391,000.00
- NXTC N/A
- Revenue This Year
- BRTX $391.52
- NXTC N/A
- Revenue Next Year
- BRTX $3.50
- NXTC N/A
- P/E Ratio
- BRTX N/A
- NXTC N/A
- Revenue Growth
- BRTX 161.54
- NXTC N/A
- 52 Week Low
- BRTX $1.21
- NXTC $0.22
- 52 Week High
- BRTX $2.55
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- BRTX 46.78
- NXTC 45.99
- Support Level
- BRTX $1.57
- NXTC $0.45
- Resistance Level
- BRTX $1.72
- NXTC $0.49
- Average True Range (ATR)
- BRTX 0.13
- NXTC 0.07
- MACD
- BRTX -0.01
- NXTC -0.01
- Stochastic Oscillator
- BRTX 20.65
- NXTC 4.63
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.